Cytel
Cytel is recorded as a service provider in 146 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 146 trials · Latest update first
A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
Sponsor Seagen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
C4221016 - A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAF V600E/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sponsor Calico Life Sciences LLC
- Start (EU)
- Latest update
- Estimated end
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available7 trial-level findings · Read insights
- Some participants who completed Period 1 did not enter Period 2, so the number starting Period 2 did not match the number completing Period 1.
- The optional actigraphy substudy was removed to reduce participant burden and simplify site logistics.
- Screening height measurement was added for adolescents to enable glomerular-filtration-rate calculation for eligibility assessment.
- An adolescent substudy was added to meet a regulatory commitment for long-term adolescent exposure.
- The blinded extension was extended from Week 136 to Week 260 to collect longer-term efficacy and safety data.
- COVID-19 procedures introduced direct-to-participant investigational-product shipment and defined limits for study-drug interruption to support continuity.
- Onsite tablet-based electronic patient-reported outcome collection was specified from Week 16.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label Extension Trial to Evaluate the Long-term Safety and Tolerability of Oral Zasocitinib (TAK-279) in Participants with Moderately to Severely Active Ulcerative Colitis and Moderately to Severely Active Crohn’s Disease
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Sponsor Mirati Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib with Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects with Moderately to Severely Active Crohn's Disease and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Sponsor Stemline Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Cytel?
The 2026-10-09 snapshot links Cytel to 146 distinct CTIS trials. Recorded services include Statistical analysis, Data Monitoring Committee, Data management, IDMC, among 49 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Cytel?
The most frequently recorded therapeutic areas are Immunology, Solid Tumor Oncology, Gastroenterology, Dermatology. Recorded phases include Phase 3, Phase 2, Phase 4, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Cytel conducted?
The linked trials record locations in 26 countries, including Spain, Italy, Germany, France, Poland. These are trial locations, not confirmed office locations or countries where Cytel delivered services.
What can this page tell me about Cytel's trial experience?
Browse 146 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Cytel. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Cytel
- Cytel Inc.